DexCom (id:7098 DXCM)
72.83 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 3:11:53 PM)
Exchange closed, opens in 18 hours 18 minutes
About DexCom
Market Capitalization 29.79B
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
| Headquarters (address) |
6340 Sequence Drive San Diego 92121 CA United States |
| Phone | 858 200 0200 |
| Website | https://www.dexcom.com |
| Employees | 9,500 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Ticker | DXCM |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 62.34 - 142.00 |
| Market Capitalization | 29.79B |
| P/E trailing | 46.22 |
| P/E forward | 37.57 |
| Price/Sale | 7.53 |
| Price/Book | 15.05 |
| Beta | 1.17 |
| EPS | 1.65 |
| EPS United States (ID:6, base:3402) | 24.22 |